Cost utility analysis of the SQ ® HDM SLIT-tablet in house dust mite allergic asthma patients in a German setting

ConclusionThis analysis indicates that ACARIZAX plus pharmacotherapy is cost-effective compared with placebo plus pharmacotherapy for house dust mite allergic asthma patients in Germany. If a disease-modifying effect can be proven the results of this analysis may underestimate the true benefits of ACARIZAX.
Source: Clinical and Translational Allergy - Category: Allergy & Immunology Source Type: research